image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

SEC Filing Details

Document Details

Form
Filing Date
June 02, 2021
Document Date
June 02, 2021
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
Nurix Therapeutics, Inc.
Issuer
NURIX THERAPEUTICS, INC.